Kidney Disease, ChronicPhase 3NCT06531824
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
A Phase 3 study testing BI 690517 and Empagliflozin in people with Kidney Disease, Chronic, run by Boehringer Ingelheim at 562 sites in 20 countries.
Trial summary
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Disease, Chronic
- What is being tested?
- BI 690517 and Empagliflozin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8,371 participants
- Where
- 562 sitesin 20 countries
- Study dates
- 30 Aug 2024to 31 Dec 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires:
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR ≥20 <45 mL/min/1.73m² (irrespective of diabetes status); or
- No self-reported diabetes: CKD-EPI eGFR ≥45 <90 mL/min/1.73m² with urine albumin-to-creatinine ratio (uACR) ≥150 mg/g (or protein-to-creatinine ratio ≥225 mg/g); or
- Self-reported diabetes: CKD-EPI eGFR ≥45 <90 mL/min/1.73m² with uACR ≥30 mg/g (or protein-to-creatinine ratio ≥45 mg/g).
- Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate.
Who cannot join
- Blood potassium of >5.2 mmol/L at screening visit
- Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) >3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred)
- Known liver cirrhosis
- On dialysis, functioning kidney transplant, or scheduled living donor transplant
- Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days
- Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor)
- Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone)
- Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.
Trial locations and contacts
562 sites in 20 countries.
562 sites in 20 countries
United Kingdom71 sites
Antrim Area Hospital
Antrim, BT41 2RL
Basildon Hospital
Basildon, SS16 5NL
Ulster Hospital
Belfast, BT16 1RH
Beltfast City Hospital
Belfast, BT9 7AB
Fernley Medical Centre
Birmingham, B11 4AN
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2WB
Burbury Medical Centre
Birmingham, B19 1TT
West Heath Surgery
Birmingham, B31 3HB
Ridgacre House Surgery
Birmingham, B32 2TJ
Oakenhurst Medical Practice
Blackburn, BB2 1AX
Royal County Sussex Hospital
Brighton, BN2 1ES
Southmead Hospital
Bristol, BS10 5NB
Pioneer Ridingleaze
Bristol, BS11 0QE
Lawrence Hill Health Centre
Bristol, BS2 0AN
Coniston Medical Practice
Bristol, BS34 5TF
West Suffolk Hospital
Bury St Edmunds, IP33 2QZ
Broomfield Hospital
Chelmsford, CM1 7ET
Hathaway Medical Centre
Chippenham, SN14 6GT
Clevedon Medical Centre
Clevedon, BS21 6DG
Queen Alexandra Hospital
Cosham, PO6 3LY
Daisy Hill Hospital
County Down, BT35 8DR
University Hospital Coventry
Coventry, CV2 2DX
The Village Surgery
Cramlington, NE23 6US
Orchard Court Surgery
Darlington, DL3 6HZ
Darent Valley Hospital
Dartford, DA2 8DA
Dorset County Hospital
Dorchester, DT1 2JY
Russells Hall Hospital
Dudley, DY1 2HQ
University Health Centre
Durham, DH1 3JX
Highland Clinical Research Facility
Fulwood, PR2 9HT
Woodlands Family Practice
Gillingham, ME7 2BU
Gloucestershire Royal Hospital
Gloucester, GL1 3NN
James Paget University Hospital
Great Yarmouth, NR31 6LA
The Garth Surgery
Guisborough, TS14 7DJ
Hereford County Hospital
Hereford, HR1 2BN
Ipswich Hospital (UK)
Ipswich, IP4 5PD
The Queen Elizabeth Hospital
Kings Lynn, PE30 4ET
Pinfold Surgery
Leeds, LS26 9AA
Ryeland Surgery
Leominster, HR6 8HD
St Luke's Hospital
Little Horton Lane, BD5 0NA
Aintree University Hospital
Liverpool, L9 7AL
North Middlesex University Hospital
London, N18 1QX
Guy's Hospital
London, SE1 9RT
King's College Hospital
London, SE5 9RS
St George's Hospital
London, SW17 0QT
Hammersmith Hospital
London, W12 0HS
Richford Gate Medical Practice
London, W6 7HY
Altnagelvin Area Hospital
Londonderry, BT47 6SB
Arrowe Park Hospital
Metropolitan Borough of Wirral, CH49 5PE
Linthorpe Surgery
Middlesbrough, TS5 6HA
Norfolk and Norwich University Hospital
Norfolk, NR4 7UY
Northampton General Hospital
Northampton, NN1 5BD
Banbury Cross Health Centre
Oxford, OX16 9AD
Churchill Hospital
Oxford, OX3 7LE
St Bartholomews & Hollow Way Med Centre
Oxford, OX4 1XB
Pickering Medical Practice
Pickering, YO18 8BL
Lilliput Surgery
Poole, BH14 8EE
Royal Berkshire Hospital
Reading, RG1 5AN
Alexandra Hospital
Redditch, B98 7UB
Salford Royal Hospital
Salford, M6 8HD
Royal Shrewsbury Hospital
Shrewsbury, SY3 8XQ
St Helens Hospital
St Helens, WA9 3DA
Lister Hospital
Stevenage, SG1 4AB
Great Western Hospital
Swindon, SN3 6BB
Royal Cornwall Hospital
Truro, TR1 3LJ
Church Street Practice
Wantage, OX12 9BN
Southend University Hospital
Westcliff-on-Sea, SS0 0RY
168 Parklands Medical Centre
Weston-super-Mare, BS24 7PR
Estuary View Medical Centre
Whitstable, CT5 3SE
Windrush Medical Practice
Witney, OX28 6JS
Eynsham Medical Centre
Witney, OX29 4QB
Woodthorpe Surgery
York, YO24 2RQ
China59 sites
Ansteel Group General Hospital
Anshan, 114000
Beijing AnZhen Hospital, Capital Medical University
Beijing, 100029
Peking University Third Hospital
Beijing, 100029
Fuwai Hospital, CAMS&PUMC
Beijing, 100037
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, 046000
The Second Hospital of Chaoyang
Chaoyang, 122000
Affiliated Hospital of Chengdu University
Chengdu, 610041
West China Fourth Hospital of Sichuan University
Chengdu, 610041
Affiliated Hospital of Chifeng University
Chifeng, 024000
The Affiliated Yongchuan Hospital of Chongqing Medical University
Chongqing, 402160
Gaoming People's Hospital
Foshan, 528500
Linquan County People's Hospital
Fuyang, 236400
Gaozhou People's Hospital
Gaozhou, 525200
Guangzhou First People's Hospital
Guangzhou, 510180
Guangzhou Red Cross Hospital
Guangzhou, 510240
The Third Affiliated Hospital of Southern Medical University
Guangzhou, 510665
The Fifth Affiliated Hospital of Southern Medical University
Guangzhou, 510925
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, 528200
Hainan General Hospital
Haikou, 570311
Shulan(Hanghzhou) Hospital
Hanghzhou, 310022
Zhejiang Hospital
Hangzhou, 310030
The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Harbin, 150001
The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Harbin, 150066
The Second People's Hospital of Hefei
Hefei, 230011
International Mongolian Hospital of Inner Mongolia
Hohot, 010010
Huangshi Central Hospital
Huangshi, 435000
Jingzhou Central Hospital
Jingzhou, 434020
Henan Jiyuan People's Hospital
Jiyuan, 454650
Liuzhou People's Hospital
Liuzhou, 545006
Oriental Hospital
Luoyang, 471000
Luoyang Third People's Hospital
Luoyang, 471002
Luoyang Central Hospital
Luoyang, 471009
Luoyang Yanshi People's Hospital
Luoyang, 471900
Meishan People's Hospital
Meishan, 620010
Jiangxi Branch Hospital of Xiangya Hospital of Central South University
Nanchang, 330000
Qingdao Cardiovascular Hospital
Qingdao, 266034
Shanghai Tenth People's Hospital
Shanghai, 200072
Shantou Central Hospital
Shantou, 515031
Second Hospital Affiliated to Shantou Medical University
Shantou, 515041
Shaoguan First People's Hospital
Shaoguan, 512000
Shaoxing Second Hospital
Shaoxing, 312000
Shenzhen Nanshan People's Hospital
Shenzhen, 518052
The Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, 518107
Shijiazhuang People's Hospital
Shijiazhuang, 050011
Songyuan Jilin Oilfield Hospital
Songyuan, 138000
Taizhou Hospital of Zhejiang Province
Taizhou, 317000
The Fourth Central Hospital of Tianjin
Tianjin, 300140
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, 830054
Wuhan Fourth Hospital
Wuhan, 430000
Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine
Wuhan, 430015
Xiamen Cardiovascular Hospital Xiamen University
Xiamen, 361006
Xinxiang Central Hospital
Xinxiang, 453000
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, 453100
The First Affiliated Hospital of Hebei North University
Zhangjiakou, 075000
The Ninth People's Hospital of Zhengzhou
Zhengzhou, 450053
Zhuhai People's Hospital
Zhuhai, 519000
Zhumadian Central Hospital
Zhumadian, 463000
Zhuzhou Central Hospital
Zhuzhou, 412000
Zhuzhou Central Hospital
Zhuzhou, 412007
India54 sites
Manipal Hospitals, Old Airport Road
Bangalore, 560017
St John's Medical College
Bangalore, 560034
Apollo Hospital - Bangalore
Bangalore, 560076
All India Institute of Medical Sciences, Bathinda
Bathinda, 151001
Apollo Hospitals - Bhubaneswar
Bhubaneswar, 751005
All India Institute of Medical Sciences Bhubaneswar
Bhubaneswar, 751019
All India Institute of Medical Sciences, Bilaspur
Bilāspur, 174001
Post Graduate Institute of Medical Education and Research
Chandigarh, 160012
Apollo Hospital - Chennai
Chennai, 600006
Apollo Speciality Hospitals, Vanagaram
Chennai, 600095
Aakash Healthcare Super Speciality Hospital
Dwārka, 110075
Accord Superspeciality Hospital
Faridabad, 121002
Amrita Hospital Faridabad
Faridabad, 121002
Marengo Asia Hospitals, Guhugram
Guhugram, 122011
Vedenta Hospitals
Guntur, 522001
Artemis Hospital
Gurugram, 122001
Karnataka Institute of Medical Sciences, Hubli
Hubli, 580021
Osmania Medical College & Hospital
Hyderabad, 500012
Apollo Hospitals Jubilee Hills
Hyderabad, 500033
Apollo DRDO Hospital
Hyderabad, 500058
Nizam's Institute of Medical Sciences
Hyderabad, 500082
Fortis Hospital, Jalandhar
Jalandhar, 144012
All India Institute of Medical Sciences, Jodhpur
Jodhpur, 342005
Amrita Institute of Medical Sciences and Research Centre
Kochi, 682041
Nil Ratan Sircar Medical College & Hospital
Kolkata, 700014
Manipal Hospitals, EM Bypass
Kolkata
IQRAA International hospital & research centre.
Kozhikode, 673009
King George's Medical University
Lucknow, 226003
Dr Ram Manohar Lohia Institute of Medical Sciences
Lucknow, 226010
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, 226014
Meenakshi Mission Hospital & Research Centre
Madurai, 625107
Apollo Speciality Hospital
Madurai, K.K. Nagar, 625020
Fortis Hospital, Manesar
Mānesar, 122052
Kasturba Medical College and Hospital
Mangaluru, 575001
Apollo BGS Hospital
Mysore, 570023
Muljibhai Patel Urological Hospital
Nadiād, 387001
Max Super Specialty Hospital, Saket
New Delhi, 110017
Epitome Kidney Urology Institute and Lions Hospital
New Delhi, 110025
Maharaja Agrasen Hospital
New Delhi, 110026
All India Institute of Medical Sciences
New Delhi, 110029
Fortis Flt. Lt. Rajan Dhall Hospital
New Delhi, 110070
Venkateshwar Hospital
New Delhi, 110075
Indira Gandhi Institute of Medical Sciences
Patna, 800014
Jawaharlal Institute of Postgraduate Medical Education
Puducherry, 605006
DKS Post Graduate Institute & Research Center, Raipur (C.G)
Raipur, 492001
All India Institute of Medical Sciences
Raipur, 492099
Raj Hospitals
Ranchi, 834001
Paras HEC, Ranchi
Ranchi, 834004
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
Rohtak, 124001
Yashoda Hospitals - Secunderabad
Secunderabad, 500003
Kimshealth
Trivandrum, 695029
Aman Hospital & Research Center
Vadodara, 390021
Christian Medical College, Vellore
Vellore, 632517
Apollo Hospitals Health City
Visakhapatnam, 530040
United States53 sites
UNM Health Science Center
Albuquerque, New Mexico, 87106
Emory University School of Medicine
Atlanta, Georgia, 30322
Research Management, Inc - Austin
Austin, Texas, 78751
Medstar Health Research Institute
Baltimore, Maryland, 21239
National Heart Institute
Beverly Hills, California, 90211
Flourish Research
Boca Raton, Florida, 33434
Advanced Heart Care, LLC
Bridgewater, New Jersey, 08807
Southwest Mississippi Nephrology, Pllc
Brookhaven, Mississippi, 39601-2326
Metrolina Nephrology Associates, PA
Charlotte, North Carolina, 28208-0014
Metrolina Nephrology Associates, PA
Charlotte, North Carolina, 28277
University of Virginia Health System
Charlottesville, Virginia, 22903
Northwestern University
Chicago, Illinois, 60611
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Kootenai Research Services
Coeur d'Alene, Idaho, 83814
Joseph Maxwell Cleland Atlanta VA Medical Center
Decatur, Georgia, 30033-4004
Dallas Nephrology Associates Medical Clinic
DeSoto, Texas, 75115-2011
Nephrology Associates, Inc
East Providence, Rhode Island, 02914-2641
Academy Of Diabetes, Thyroid And Endocrine, PA
El Paso, Texas, 79935
University of Florida Health Shands Hospital
Gainesville, Florida, 32608
Carolina Kidney Associates
Greensboro, North Carolina, 27405-3654
Apogee Clinical Research
Huntsville, Alabama, 35805-4104
Florida Kidney Physicians LLC
Jacksonville Beach, Florida, 32250-4303
University of Kansas Medical Center
Kansas City, Kansas, 66160
South Denver Cardiology Associates
Littleton, Colorado, 80120
University of Louisville
Louisville, Kentucky, 40202
P&I Clinical Research, LLC
Lufkin, Texas, 75904
Texas Institute for Kidney and Endocrine Disorders
Lufkin, Texas, 75904
East Coast Institute For Research LLC
Macon, Georgia, 31210-1359
Kidney and Hypertension Specialists, PLLC
Manassas, Virginia, 20110
University of Tennessee
Memphis, Tennessee, 38104
Total Research Group, LLC
Miami, Florida, 33126
Bioresearch Partner
Miami, Florida, 33127
Minneapolis VA Health Care System
Minneapolis, Minnesota, 55417
VA New York Harbor Healthcare System
New York, New York, 10010-5011
Tidewater Physicians Multispecialty Group
Newport News, Virginia, 23606
VA Southern Nevada Healthcare System
North Las Vegas, Nevada, 89086
Great Plains Nephrology
North Platte, Nebraska, 69101-0614
Renal Specialists of Houston, PA
Pasadena, Texas, 77504-1944
Northeast Endocrine Metabolic Associates
Philadelphia, Pennsylvania, 19114-1028
Temple University
Philadelphia, Pennsylvania, 19140
Seacoast Kidney and Hypertension Specialists
Portsmouth, New Hampshire, 03801
Sierra Nevada Specialty Care
Reno, Nevada, 89511
Lake Michigan Nephrology
Saint Joseph, Michigan, 49085-8511
Salem VA Medical Center
Salem, Virginia, 24153
University Health
San Antonio, Texas, 78207
St. Clair Nephrology Research, LLC
Shelby, Michigan, 48315
Providence Medical Research Center
Spokane, Washington, 99204
Southwest Kidney Institute
Surprise, Arizona, 85374-4840
Olive View - UCLA Medical Cente
Sylmar, California, 91342
Clinical Renal Associates
Upland, Pennsylvania, 19013
Interventional Cardiology Medical Group
West Hills, California, 91307
Kansas Nephrology Research Institute, LLC
Wichita, Kansas, 67214
Brookview Hills Research Associates LLC
Winston-Salem, North Carolina, 27103
Germany52 sites
Universitätsklinikum Aachen, AöR
Aachen, 52074
KfH-Nierenzentrum Bad Kreuznach
Bad Kreuznach, 55543
Nephrologische Gemeinschaftspraxis Bad Nenndorf
Bad Nenndorf, 31542
Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
Bad Oeynhausen, 32545
Vivantes Klinikum im Friedrichshain
Berlin, 10249
Praxis für Nierenkrankheiten und Dialyse Helle Mitte
Berlin, 12627
Universitätsklinikum Bonn AöR
Bonn, 53127
Städtisches Klinikum Braunschweig gGmbH
Braunschweig, 38126
St.-Josefs-Hospital Cloppenburg
Cloppenburg, 49661
KfH Nierenzentrum Coburg
Coburg, 96450
Klinikum Dortmund gGmbH
Dortmund, 44137
Universitätsklinikum Düsseldorf
Düsseldorf, 40225
Dialysezentrum Elsenfeld
Elsenfeld, 63820
ClinPhenomics CVC GmbH
Frankfurt, 60596
Agaplesion Markus Krankenhaus
Frankfurt am Main, 60431
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596
Nierenzentrum Freiburg
Freiburg im Breisgau, 79100
Universitätsklinikum Gießen und Marburg GmbH
Giessen, 35392
Universitätsmedizin Greifswald
Greifswald, 17489
Universitätsklinikum Halle (Saale) AöR
Halle, 06097
Universitätsklinikum Hamburg, Eppendorf
Hamburg, 20246
Medizinische Hochschule Hannover
Hanover, 30625
Zentrum Für Nieren Hochdruck und Stoffwechselerkrankungen
Hanover, 30625
BAG für Nephrologie und Dialyse
Heilbronn, 74076
Ruhr-Universität Bochum
Herne, 44625
Universität des Saarlandes
Homburg, 66421
Universitätsklinikum Jena
Jena, 07747
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105
Klinikum Konstanz
Konstanz, 78464
KfH-Nierenzentrum Kronach
Kronach, 96317
Dr. Vehling-Kaiser MVZ GmbH
Landshut, 84036
KfH Nierenzentrum Leipzig
Leipzig, 04129
Nephrologisches Zentrum Emsland
Lingen, 49808
Otto-von-Guericke-Universität Magdeburg
Magdeburg, 39120
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, 55131
Klinikum der Universität München - Campus Innenstadt
München, 80336
Klinikum rechts der Isar der Technischen Universität München
München, 81675
Dialysezentrum Neckarsulm
Neckarsulm, 74172
Universitätsklinikum Ruppin-Brandenburg
Neuruppin, 16816
Klinikum Nürnberg
Nuremberg, 90471
Universitätsmedizin Rostock
Rostock, 18057
Dialysezentrum Rotenburg
Rotenburg (Wümme), 27356
MVZ Dialysezentrum Schweinfurt
Schweinfurt, 97421
Städtisches Klinikum Solingen gGmbH
Solingen, 42653
Nephrologische Gemeinschaftspraxis Springe
Springe, 31832
Robert-Bosch-Krankenhaus GmbH
Stuttgart, 70376
KfH-Nierenzentrum Traunstein
Traunstein, 83278
Medizinisches Versorgungszentrum der Barmherzigen Brüder Trier gGmbH
Trier, 54292
Nephrologisches Zentrum Villingen-Schwenningen
Villingen-Schwenningen, 78052
Nierenzentrum Wiesbaden
Wiesbaden, 65191
Helios Universitätsklinikum Wuppertal
Wuppertal, 42283
Universitätsklinikum Würzburg AÖR
Würzburg, 97078
Brazil32 sites
Centro de Pesquisa Clínica do Coração
Aracaju, 49055-530
Santa Casa de Belo Horizonte
Belo Horizonte, 30150-320
Centro de Pesquisa do Hospital Evangelico de Belo Horizonte
Belo Horizonte, 30220-330
Universidade Estadual Paulista "Julio De Mesquita Filho"
Botucatu, 18618-686
Hospital Universitário São Francisco na Providência de Deus
Bragança Paulista, 1291-6542
CEG - Centro de Endocrinologia Geloneze
Campinas, 13073-350
Instituto Cardiovascular de Linhares Ltda
Centro Linhares, 29900010
PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PR
Curitiba, 80230-130
Hospital Universitário Walter Cantidio - UFC
Fortaleza, 60416-000
Centro de Pesquisas em Diabetes e Doencas Metabolicas
Fortaleza, 60430-350
Clínica CENDI Endocrinologia e Diabetes
Goiânia, 74230-035
Hospital Ruy Azeredo
Goiânia, 74453200
Fundação Pró-Rim Joinville
Joinville, 89227-680
Galileo Medical Research Ltda
Juiz de Fora, 36033-318
Centro de Pesquisas Clínicas Dr. Marco Mota
Maceió, 57051-160
Hospital Universitário Onofre Lopes
Natal, 59012300
Hospital de Clinicas de Porto Alegre
Porto Alegre, 90035-903
Hospitalar Moinhos de Vento
Porto Alegre, 90560-032
Hospital Sao Lucas da PUCRS
Porto Alegre, 90610-000
IMIP Pernambuco
Recife, 50070902
AME Saúde
Recife, 50720110
Hospital das Clinicas da Universidade Federal de Pernambuco
Recife, 50740900
Fundação Bahiana de Infectologia
Salvador, 40110160
CEMEC - Centro Multidisciplinar de Estudos Clínicos
São Bernardo do Campo, 09715-090
Hospital de Base
São José do Rio Preto, 15090-000
CIPES - Centro Internacional de Pesquisa Clínica
São José dos Campos, 12230-001
Instituto de Assistência Médica ao Servidor Público Estadual de São Paulo
São Paulo, 0402-9001
Fundacao Oswaldo Ramos (Hospital do Rim)
São Paulo, 04023900
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, 05403-000
Hospital Universitário da Universidade Federal do Piauí
Teresina, 64049550
Hospital Universitário Cassiano Antônio Moraes
Vitória, 29043-260
Clínica Cardiológica
Votuporanga, 15505-189
Italy32 sites
Ospedale SS. Antonio e Biagio e C. Arrigo - AOUAL
Alessandria, 15121
Asti-Ospedale Cardinal Massaia
Asti, 14100
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
Bari, 70124
ASST Papa Giovanni XXIII
Bergamo, 24127
Policlinico S. Orsola-Malpighi
Bologna, 40138
Azienda Ospedaliera ARNAS G. Brotzu
Cagliari, 09100
Chieri-Ospedale Maggiore
Chieri, 10023
Ospedale SS Annunziata
Chieti, 66100
A.S.O. S. Croce e Carle
Cuneo, 12100
Firenze-Ospedale San Giovanni di Dio
Florence, 50124
A. O. Universitaria Careggi
Florence, 50134
Azienda Ospedaliera San Martino
Genova, 16132
Ospedale di Imola S. Maria della Scaletta
Imola, 40026
Ospedale San Raffaele S.r.l.
Milan, 20132
Asst Santi Paolo E Carlo
Milan, 20142
Fondazione IRCCS San Gerardo dei Tintori
Monza, 20900
Ospedale Maggiore della Carità
Novara, 28100
Azienda Ospedaliera di Padova
Padova, 35128
Azienda Ospedaliera Unversitaria di Parma
Parma, 43126
Fondazione Salvatore Maugeri
Pavia, 27100
Azienda Ospedaliera di Perugia
Perugia, 06129
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126
Prato-Ospedale Santo Stefano
Prato, 59100
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
Roma, 00189
Azienda Socio Sanitaria Territoriale Lariana
San Fermo della Battaglia, 22020
IRCCS Ospedale "Casa Sollievo della Sofferenza"
San Giovanni Rotondo (Foggia), 71013
Azienda Socio Sanitaria Ligure 2
Savona, 17100
IRCCS MultiMedica
Sesto San Giovanni, 20099
Todi-Nuovo Ospedale Media Valle del Tevere
Todi, 06059
Torino-Ospedale Oftalmico
Turin, 0100
Ospedale Castelli - Verbania
Verbania, 28922
Ospedale San Bortolo
Vicenza, 36100
Malaysia26 sites
Hospital Ampang
Ampang, 68000
Hospital Selayang
Batu Caves, 68100
Hospital Sultanah Nora Ismail
Batu Pahat, 83000
Hospital Pulau Pinang-Pulau Pinang-21953
George Town, 10990
Hospital Raja Permaisuri Bainun
Ipoh, 30450
Hospital Sultanah Aminah
Johor Bahru, 80100
Hospital Sultan Ismail
Johor Bahru, 81100
Hospital Sultan Idris Shah Serdang
Kajang, 43000
Hospital Kajang
Kajang, Selangor, 43000
Hospital Tengku Ampuan Rahimah
Klang, 41200
Hospital Raja Perempuan Zainab II
Kota Bharu, 15586
Hospital Queen Elizabeth
Kota Kinabalu, 88586
Hospital Kuala Lumpur
Kuala Lumpur, 50586
University Malaya Medical Centre
Kuala Lumpur, 59100
Hospital Tuanku Ampuan Najihah
Kuala Pilah, 72000
Hospital Tengku Ampuan Afzan
Kuantan, 25100
Hospital Umum Sarawak
Kuching, 93586
Hospital Kulim
Kulim, 09090
Hospital Melaka
Malacca, 75400
Hospital Pakar Sultanah Fatimah
Muar town, 84000
Hospital Seberang Jaya
Perai, 13700
Hospital Sultan Abdul Aziz Shah
Serdang, 43400
Hospital Tuanku Ja'afar
Seremban, 70300
Hospital Taiping
Taiping
Hospital Teluk Intan
Teluk Intan, 36000
Hospital Sultan Haji Ahmad Shah
Temerluh, 28000
Japan25 sites
Asahikawa Medical University Hospital
Asahikawa-Shi, 078-8510
Chiba University Hospital
Chiba, 260-8677
University of Yamanashi Hospital
Chuo-Shi, 409-3898
Kyushu University Hospital
Fukuoka, 812-8582
Tokai University Hospital
Isehara, 259-1193
Shimane University Hospital
Izumo, 693-8501
Kawasaki Medical School Hospital
Kurashiki-Shi, 701-0192
Kurume University Hospital
Kurume, 830-0011
Kyoto University Hospital
Kyoto, 606-8507
Aichi Medical University Hospital
Nagakute, 480-1195
Chubu Rosai Hospital
Nagoya, 455-8530
Nagoya University Hospital
Nagoya, 466-8560
Okayama University Hospital
Okayama, 700-8558
Kansai Electric Power Hospital
Osaka, 553-0003
Shiga University of Medical Science Hospital
Ōtsu, 520-2192
Tohoku University Hospital
Sendai, 980-8547
St. Luke's International Hospital
Tokyo, 104-8560
Toranomon Hospital
Tokyo, 105-8470
Juntendo University Hospital
Tokyo, 113-8431
The University of Tokyo Hospital
Tokyo, 113-8655
Keio University Hospital
Tokyo, 160-8582
National Center for Global Health and Medicine
Tokyo, 162-8655
Teikyo University Hospital
Tokyo, 173-8606
Tokyo-Eki Center-building Clinic
Tokyo, Chuo-ku, 103-0027
Yokohama City University Hospital
Yokohama, 236-0004
Canada24 sites
Centricity Research (Brampton)
Brampton, Ontario, L6S 0C6
Centricity Research (Vaughan)
Concord, Ontario, L4K 4M2
University of Alberta Hospital (University of Alberta)
Edmonton, Alberta, T6G 2P4
Centre for Clinical Research
Halifax, Nova Scotia, B3H 1V7
Royal Inland Hospital
Kamloops, British Columbia, V2C 2T1
Kelowna General Hospital
Kelowna, British Columbia, V1Y 1T2
Queen's University
Kingston, Ontario, K7L 3N6
London Regional Cancer Program - London Health Sciences Ctr.
London, Ontario, N6A 5W9
CIUSSS de l'Est-de-l'Île-de-Montréal
Montreal, Quebec, H1T 2M4
McGill University Health Centre (MUHC)
Montreal, Quebec, H3G 1A4
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, H2X 0A9
Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9
The Ottawa Hospital
Ottawa, Ontario, K1H 7W9
Northern Health
Prince George, British Columbia, V2M 1S2
CIUSSS Nord de l'île de Montreal
Québec, Montréal, H4J 1C5
CHU de Quebec-Universite Laval Research Centre
Québec, G1R 2J6
Diex Recherche Québec
Québec, G1V 4T3
CIUSSS de l Estrie-CHUS
Sherbrooke, Quebec, J1H 5N4
Fraser Health
Surrey, British Columbia, V3W 1J8
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4G 3E8
St. Michael's Hospital
Toronto, Ontario, M5C2T2
Toronto General Hospital
Toronto, Ontario, M5G 2N2
St. Paul's Hospital (Vancouver)
Vancouver, British Columbia, V1Y 1S1
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
Mexico20 sites
Centenario Hospital Miguel Hidalgo
Aguascalientes, 20259
Instituto de Diabetes, Obesidad y Nutrición S.C.
Cuernavaca, 62250
Neurociencias Estudios Clinicos S.C.
Culiacán, CP 80020
Instituto de investigación aplicado a la neurociencia
Durango, 34000
Centro de Investigacion Clinica y Medicina Traslacional (CIMeT)
Guadalajara, 44340
Centro Medico Nacional de Occidente/ Centro De Investigacion Biomedica De Occidente
Guadalajara, 44340
Unidad de Investigación Clinica y Atencion Medica HEPA SC
Guadalajara, 44670
Medical Care & Research SA de CV
Mérida, 97070
Merida Investigación Clínica
Mérida, 97125
Health Pharma Professional Research S.A. de C.V.
Mexico City, 03100
Soluciones Terapéuticas Médico Quirúrgicas S. de R.L. de C.V.
Mexico City, 03650
Hospital Juárez de México
Mexico City, 07760
Iecsi S.C.
Monterrey, 64310
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, 64460
Renall Monterrey
Monterrey, CP 64040
Centro de Investigación Clínica Chapultepec S.A. de C.V.
Morelia, 58260
IMSS Regional General Hospital 180
Tlajomulco de Zúñiga, 45653
Instituto Nacional de Cardiologia Ignacio Chavez
Tlalpan, 14080
FAICIC S de RL de C.V.
Veracruz, 91900
Sociedad de Metabolismo y Corazón S.C.
Veracruz, 91910
Taiwan20 sites
E-Da Hospital
Kaohsiung City, 824005
Lotung Poh-Ai Hospital
Luodong Township, 265
Far Eastern Memorial Hospital
New Taipei City, 220
Taipei Tzu Chi Hospital
New Taipei City, 23142
Taipei Medical University-Shuang Ho Hospital
New Taipei City, 23561
Fu Jen Catholic University Hospital
New Taipei City, 243089
Chung Shan Medical University Hospital
Taichung, 402
China Medical University Hospital
Taichung, 404
Taichung Veterans General Hospital
Taichung, 407219
Tungs' Taichung MetroHarbor Hospital
Taichung, 435
National Cheng Kung University Hospital
Tainan, 70403
Chi Mei Hospital, Liouying
Tainan, 736402
Mackay Memorial Hospital
Taipei, 10449
Cathay General Hospital
Taipei, 106
Taipei Medical University Hospital
Taipei, 110
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, 111045
Taipei Veterans General Hospital
Taipei, 112
Taipei Municipal Wanfang Hospital
Taipei, 11696
TaoYuan General Hospital
Taoyuan City, 330
Chang Gung Memorial Hospital, Linkou
Taoyuan City, 333
Argentina19 sites
Fundacion INTECNUS
Bariloche, 8500
Terapia Renal Domiciliaria
Buenos Aires, 1407
Centro de Salud Renal Junin SRL
Buenos Aires, B6000
Dres. Iribarren & Asoc. Consultario
Buenos Aires, C1061AAE
Glenny Corp - Centro Medico Saavedra
Buenos Aires, C1430CKE
CPSIC SRL - Cardiologia Palermo
CABA, 1425
Sanatorio Pasteur S.A
Catamarca, K4703AFI
CEMIC
Ciudad Autonoma Buenos Aires, C1431FWO
CIMEL Chahin - Chahin S.A.
Lanús Este, B1824KAJ
Centro Nefrologico del Mar
Mar del Plata, B7612
Mains Bleues
Rafaela, S2300
Hospital Privado de Rosario
Rosario, S2000GAP
Sanatorio Parque S.A.
Rosario, S2013
Instituto de Nefrourologia y Nutricion de Salta
Salta, A4400
Clinica El Castaño
San Juan, J5400
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, 4000
Centro Integral de Medicina Respiratoria - CIMER
San Miguel de Tucumán, 4000
Instituto de Investigaciones Clinicas de Rosario
Santa Fe, 2000
CEREHA S.A.- Centro de Estudios Renales e Hipertension Arterial
Villa Domínico, B1872EEB
Australia18 sites
Flinders Medical Centre
Bedford Park, South Australia, 5042
Eastern Health-Box Hill Hospital
Box Hill, Victoria, 3128
Concord Hospital
Concord, New South Wales, 2139
Renal Research, Gosford
Gosford, New South Wales, 2250
Austin Health
Heidelberg Heights, Victoria, 3081
Nepean Hospital
Kingswood, New South Wales, 2747
St George Hospital
Kogarah, New South Wales, 2217
Liverpool Hospital
Liverpool, New South Wales, 2170
The Alfred Hospital
Melbourne, Victoria, 3004
St Vincent's Hospital Melbourne
Melbourne, Victoria, 3065
Macquarie University
New South Wales, 2019
Westmead Hospital
New South Wales, 2145
Hervey Bay Hospital
Pialba, Queensland, 4655
Port Macquarie Base Hospital (PMBH)
Port Macquarie, New South Wales, 2444
AOVO Clinical Trials
Southport, Queensland, 4215
Griffith University
Southport, Queensland, 4222
Sunshine Hospital
St Albans, Victoria, 3021
Toowoomba Hospital
Toowoomba, Queensland, 4350
South Korea18 sites
Korea University Ansan Hospital
Ansan-si, 15355
Pusan National University Hospital
Busan, 49241
Soon Chun Hyang University Hospital Cheonan
Cheonan-si, 31151
Chungbuk National University Hospital
Cheongju-si, 28644
Kyungpook National University Hospital
Daegu, 41944
Keimyung University Dongsan Hospital
Deagu, 42601
Inje University Ilsan Paik Hospital
Goyang-si, 10380
Hanyang University Guri Hospital
Guri-si, 11923
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong, 14353
The Catholic University of Korea, Incheon St. Mary's Hospital
Incheon, 21431
CHA Bundang Medical Center
Seongnam-si, 13496
Seoul National University Hospital
Seoul, 03080
Severance Hospital
Seoul, 03722
Gangnam Severance Hospital
Seoul, 06273
SMG-SNU Boramae Medical Center
Seoul, 07061
The Catholic University of Korea, Yeouido St.Mary's Hospital
Seoul, 07345
Korea University Guro Hospital
Seoul, 08308
Yonsei University Wonju Severance Christian Hospital
Wŏnju, 26426
Portugal14 sites
ULS da Região de Aveiro
Aveiro, 3814-501
Centro Clínico Académico de Braga (2CA-Braga)
Braga, 4710-243
CHLO, EPE - Hospital de Santa Cruz
Carnaxide, 2790-134
Unidade Local de Saúde de Castelo Branco, E.P.E
Castelo Branco, 6000-085
CHUC - Centro Hospitalar e Universitario de Coimbra, EPE
Coimbra, 3004-561
Unidade Local de Saúde do Algarve, E.P.E
Faro, 8000-386
SESARAM
Funchal, 9004-514
ULS de São José
Lisbon, 1069-166
Unidade Local de Saúde Santa Maria
Lisbon, 1649-035
Hospital Beatriz Ângelo
Loures, 2674-514
Centro Hospitalar Universitário São João,EPE
Porto, 4200-319
Unidade Local de Saúde de Matosinhos
Senhora da Hora, 4464-513
Unidade Local De Saude Da Arrabida E.P.E.
Setúbal, 2910-549
Unidade Local De Saude De Viseu Dao-Lafoes E.P.E.
Viseu, 3504-509
Denmark7 sites
Aalborg Universitetsshospital
Aalborg, 9000
Rigshospitalet, København
Copenhagen, 2100
Herlev and Gentofte Hospital
Herlev, 2730
Steno Diabetes Center Copenhagen
Herlev, 2730
Kolding Hospital
Kolding, 6000
Odense University Hospital
Odense, 5000
Zealand University Hospita; Roskilde
Roskilde, 4000
New Zealand7 sites
Auckland City Hospital
Auckland, 1023
Middlemore Hospital
Auckland, 2025
North Shore Hospital
Auckland, Takapuna, 0620
Dunedin Hospital
Dunedin, Otago, 9016
Waikato Hospital
Hamilton, Waikato Region, 3240
Taranaki Base Hospital
New Plymouth, 4310
Whangarei Hospital
Whangarei, Northland, 0110
Sweden7 sites
Danderyds Sjukhus AB
Danderyd, 182 88
Sahlgrenska Universitetsjukhuset
Gothenburg, 413 46
Universitetssjukhuset Linköping
Linköping, 581 85
Skånes Universitetssjukhus, Lund
Lund, 221 85
Karolinska University Hospital
Stockholm, 14157
Region Vaesternorrland
Sundsvall, 856 43
Akademiska sjukhuset
Uppsala, 751 85
Belgium4 sites
AZ Sint-Jan Brugge
Bruges, 8000
Ziekenhuis Oost-Limburg
Genk, 3600
UZ Brussel
Jette, 1090
Centre Hospitalier Universitaire de Liège
Liège, 4000
About this study
Official title: A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.
After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study.
The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.
- Conditions
- Kidney Disease, Chronic
- Being tested
- BI 690517, Placebo matching BI 690517, Empagliflozin
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BI 690517Drug
Also called Vicadrostat
BI 690517 (called Type M randomized treatment)
Placebo matching BI 690517Drug
Placebo matching BI 690517
EmpagliflozinDrug
Empagliflozin (called Type E)
| Study group | Role | What they receive |
|---|---|---|
| Part 1: Run-in period (all participants) | Other | * Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M).
* This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization. Receives: Drug: Empagliflozin |
| Part 2: Randomized treatment, follow-up period, treatment group | Experimental | Not described Receives: Drug: BI 690517; Drug: Empagliflozin |
| Part 2: Follow-up period, placebo group | Placebo comparator | Not described Receives: Drug: Placebo matching BI 690517; Drug: Empagliflozin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.
Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization
Measured: up to 4 years
Secondary outcomes (6)
Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death
Measured: up to 4 years
Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death
Measured: up to 4 years
Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause
Measured: up to 4 years
Key secondary outcome: Time to death from any cause
Measured: up to 4 years
Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)
Measured: up to 4 years
Time to first event of kidney disease progression or cardiovascular death
Measured: up to 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2024
- Study start30 Aug 2024
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney Disease, ChronicStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Part 1: Run-in period, non randomized, single arm Part 2: Randomized (BI 690517 or placebo), double-blind, placebo-controlled follow-up period
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 8,371 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06531824
- Sponsor's protocol ID
- 1378-0006
- Other IDs
- 2024-511025-63-00, U1111-1306-5049
- Status last verified
- Oct 2026
- First submitted
- 29 Jul 2024
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT06531824
- Acronym / sponsor ID
- 1378-0006
- Conditions
- Kidney Disease, Chronic
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 8,371 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- 30 Aug 2024 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 1 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.
After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study.
The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Part 1: Run-in period, non randomized, single arm Part 2: Randomized (BI 690517 or placebo), double-blind, placebo-controlled follow-up period
| Arm | Type | Receives |
|---|---|---|
| Part 1: Run-in period (all participants) | Other | Drug: Empagliflozin* Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M). * This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization. |
| Part 2: Randomized treatment, follow-up period, treatment group | Experimental | Drug: BI 690517, Drug: Empagliflozin |
| Part 2: Follow-up period, placebo group | Placebo comparator | Drug: Placebo matching BI 690517, Drug: Empagliflozin |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires:
- Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate.
Key exclusion criteria (8 listed)
- Blood potassium of >5.2 mmol/L at screening visit
- Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) >3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred)
- Known liver cirrhosis
- On dialysis, functioning kidney transplant, or scheduled living donor transplant
- Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BI 690517Also: VicadrostatBI 690517 (called Type M randomized treatment) | Drug | Part 2: Randomized treatment, follow-up period, treatment group |
| Placebo matching BI 690517Placebo matching BI 690517 | Drug | Part 2: Follow-up period, placebo group |
| EmpagliflozinEmpagliflozin (called Type E) | Drug | Part 1: Run-in period (all participants), Part 2: Follow-up period, placebo group, Part 2: Randomized treatment, follow-up period, treatment group |
Primary outcome
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.
Time frame: up to 4 years
Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization
6 secondary outcomes
Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death
Time frame: up to 4 years
Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death
Time frame: up to 4 years
Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause
Time frame: up to 4 years
Key secondary outcome: Time to death from any cause
Time frame: up to 4 years
Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)
Time frame: up to 4 years
Time to first event of kidney disease progression or cardiovascular death
Time frame: up to 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Related trials for Kidney Disease, Chronic
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
562 sites in 20 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing BI 690517 and Empagliflozin in people with Kidney Disease, Chronic, run by Boehringer Ingelheim at 562 sites in 20 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 562 sites in United Kingdom, China, India, United States, Germany and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death. (time frame: up to 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.